Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10291261 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4MEN1 | |
| SCHEMBL10290198 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4MEN1 | |
| SCHEMBL19522452 | 0.83 | TSHR (0.36) | MEN1TSHRKMT2A | |
| SCHEMBL19522458 | 0.83 | TSHR (0.36) | MEN1TSHRKMT2A | |
| SCHEMBL10257664 | 0.83 | TSHR (0.36) | MEN1TSHRKMT2A | |
| SCHEMBL19522400 | 0.83 | TSHR (0.36) | MEN1TSHRKMT2A | |
| SCHEMBL10290386 | 0.83 | HDAC2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4KISS1R | |
| SCHEMBL22294481 | 0.82 | ALDH1A1 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4MEN1 | |
| SCHEMBL12352400 | 0.82 | ALDH1A1 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4MEN1 | |
| SCHEMBL22294295 | 0.82 | ALDH1A1 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802939-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-23 | — | — | US | disclosed |
| US-8940720-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | CHRNB2 4592/4885CHRNB4 4574/4885CHRNA3 4495/4885 |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | CHRNB2 4592/4885CHRNB4 4574/4885CHRNA3 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.